Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: Biocon Biologics

FY18 Revenue Rs 4,336 Cr; EBITDA at Rs 1,035 Cr; Net Profit at Rs 372 Cr


Bengaluru, Karnataka, India: April 26, 2018:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, today announced its consolidated financial results for the fourth quarter and fiscal year ended March 31st, 2018.

Commenting on the highlights, Chairperson & Managing Director, Kiran Mazumdar-Shaw stated:
“We concluded the year with a strong revenue growth of 27% in Q4FY18 led by Biologics and Research Services businesses, which grew 47% and 45%, respectively. Our traditional Small Molecules and Branded Formulations businesses also turned in a positive performance this quarter. We crossed a key milestone in Q4 when our Insulin Glargine, received regulatory approvals in the developed markets of Europe and Australia. Our biosimilar Trastuzumab also got approval in Turkey.
“The muted FY18 performance was on account of continued pricing challenges in the generics business coupled with a planned plant shut down for requalification and lower licensing income in the biologics business. In addition, operational expenses related to our Malaysia facility impacted the bottom line. However, a positive Q4 is indicative of a normalized business trend. Recent approvals of our biosimilars along with the strong performance of Syngene are expected to positively impact overall performance in FY19.”


  • Semglee™, Insulin Glargine co-developed by Biocon and Mylan, is the first biosimilar from the partnered portfolio to be approved in the developed markets of EU and Australia.
  • Biocon also received Insulin Glargine approval in South Korea and biosimilar Trastuzumab approval in Turkey.
  • Biocon and Mylan, agreed to accelerate the introduction of biosimilar Adalimumab in Europe through Mylan’s in-licensing arrangement with Fujifilm Kyowa Kirin Biologics, to enable launch in EU, around market formation.
  • Biocon and Mylan, have agreed to expand their long-standing collaboration to add two new next-generation biosimilar programs with Insulin Glargine 300 units/mL and Pertuzumab.


As per IND-AS In Rs Crore, except growth numbers

Particulars  Q4FY18 Q4FY17 Growth FY18 FY17 Growth
Small Molecules 426 395 8% 1,508 1,641 -8%
Biologics 241 163 47% 770 702 10%
Branded Formulations 149 131 14% 612 549 11%
Research Services 409 283 45% 1,423 1,193 19%
Inter-segment (55) (41) 35% (183) (163) 13%
Revenue from Operations# 1,170 931 26% 4,130 3,922 5%
Other Income 67 43 56% 206 157 31%
TOTAL REVENUE 1,237 974 27% 4,336 4,079 6%
EBITDA 300 231 30% 1,035 1,137 -9%
Interest & Finance charges 17 5 238% 61 26 137%
Depreciation & Amortisation 95 73 31% 385 277 39%
PBT 193 159 22% 610 850 -28%
Net Profit 130 127 2% 372 612 -39%
R&D Expenses in P&L 51 65 -22% 216 267 -19%
Gross R&D Spends 98 98 0% 380 402 -5%
EBITDA Margin 24% 24% 24% 28%
Core EBITDA Margin 26% 30% 27% 32%
Net Profit Margin 11% 13% 9% 15%
#includes Licensing Income 2 16 23 145

Notes: Figures above are rounded off to the nearest Cr; % based on absolute numbers.



Biocon’s Total Revenue for Q4FY18 stood at Rs 1,237 grew by 27% Crore with Revenue from Operations at RS 1,170 Crore growing by 26%.

EBITDA grew 30% at Rs 300 Crore, with an EBITDA margin of 24% for Q4FY18. Core EBITDA margin for Q4FY18 (net of licensing, impact of forex and R&D) stood at 26%.

Reported Net Profit for the quarter was Rs 130 Crore, which represents a Net Profit margin of 11%.

Licensing Income for the quarter was Rs 2 Crore and Other Income stood at Rs 67 Crore.

Net R&D expenses for the quarter stood at Rs 51 Crore while Gross R&D expenses were Rs 98 Crore corresponding to 13% of our operating revenue (excluding Syngene).


Biocon’s Total Revenue for Q4FY18 stood at Rs 4,336 with Revenue from Operations at Rs 4,130 Crore.

EBITDAstood at Rs 1,035 Crore, with an EBITDA margin of 24% for FY18. Core EBITDA margin for FY18 (net of licensing, impact of forex and R&D) stood at 27%.

Reported Net Profit for the year was Rs 372 Crore, which represents a Net Profit margin of 9%.

Other Income stood at Rs 206 Crore in 2018

Licensing Income for the year declined 84% to Rs 23 Crore in FY18.

Net R&D expenses for FY18 stood at Rs 216 Crore while Gross R&D expenses were Rs 380 Crore representing 14% of our operating revenue (excluding Syngene)

The overall profitability for FY18 was largely impacted due to pricing pressures in generics business, lower licensing income in biologics, planned shut down for plant requalification post regulatory audits and inclusion of fixed and operating costs related to the Malaysia facility.

Recent regulatory approvals of our biosimilars coupled with strong performance by Syngene bode well for FY19. While market dynamics for Small Molecules and India Branded Formulations remain challenging, we expect the segments to recover from the pressures faced in FY18, going forward.


SMALL MOLECULES: APIs & Generic Formulations

The Small Molecules business reported a revenue growth of 8% for the quarter at Rs 426 Crore. This was largely led by a higher uptake in key statins & Rosuvastatin formulations and a steady performance by immunosuppressants. Regulatory filings for key APIs in developed and emerging markets prepare the business for a better play, going forward. Generic formulations business is on track with a few ANDA submissions being made in Q4.

BIOLOGICS: Biosimilars & Novels

The Biologics vertical, comprising Novel Biologics and Biosimilars, recorded a strong growth of 47% at Rs 241 Crore in the quarter, led by Insulins as well as biosimilar monoclonal antibodies (mAbs).

The strong growth in Insulins business was driven by a good traction in key markets like Mexico, Malaysia and the AFMET region. The sales of mAbs were largely boosted by the expansion of our biosimilar Trastuzumab footprint in emerging markets.

However, on an annual basis, the Biologics business growth was muted due to higher licensing income in the previous year and planned plant shut down for requalification post audit. Excluding Licensing Income, Biologics reported a growth of 29% in FY18.


Insulins & Analogs: Regulatory & Other Developments

The approval of our biosimilar Insulin Glargine Semgle™ by the European Commission (EC) in Q4FY18, following a positive recommendation earlier by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), was an important milestone for our Insulins business.

Semgle™ 100 units/mL 3 mL prefilled disposable pen, is the first biosimilar from Biocon and Mylan’s joint portfolio to be approved in Europe. Additionally, Semgle™ 100 IU/mL 3 mL prefilled pen was approved by the Therapeutic Goods Administration (TGA), Australia. The EC approval of Semgle™ applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein.

Semgle™ is expected to be launched by our partner Mylan in Australia and Europe in the second half of CY 2018.

Biocon also obtained regulatory approvals for biosimilar Insulin Glargine in South Korea and our local partner is expected to commercialize the product later this year.

In the U.S., Mylan’s application for Insulin Glargine under the NDA pathway is under review by the Food & Drug Administration (FDA).

For Insulin Aspart we just completed our Phase I study and expect comparative PK/PD results in H1FY19.

Monoclonal Antibodies & Recombinant Proteins: Regulatory & Other Developments

In order to accelerate the introduction of biosimilar Adalimumab in Europe, Biocon and Mylan agreed for an in-licensing arrangement between Mylan and Fujifilm Kyowa Kirin Biologics (FKB).

FKB’s product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018, clearing the way for a potential launch by Mylan around market formation. Biocon retains its economic interest in this arrangement vis-a-vis Mylan, in line with our existing global collaboration for monoclonal antibodies.

Biocon and Mylan have also agreed to expand their long-standing collaboration with the addition of two new next-generation biosimilars, Insulin Glargine 300 units /mL and Pertuzumab. This will bolster our existing global biosimilars portfolio comprising antibodies & insulin analogs.

During the quarter, our Trastuzumab became the first biosimilar Trastuzumab to be approved in Turkey which is the 4th largest emerging market for this molecule. This approval enables us to expand access to this lifesaving therapy for breast cancer patients in Turkey.

In Europe, the regulatory review of our Marketing Authorization Applications (MAAs) for biosimilar Trastuzumab and Pegfilgrastim are progressing well and we expect decisions by CHMP by end of CY 2018.

The review of our Biologics License Application (BLA) for biosimilar Pegfilgrastim by USFDA is progressing. We have responded to all information requests received till date and are awaiting their response by June 4, 2018. The global Phase III trial of our biosimilar Bevacizumab continues to make good progress.

Novel Biologics

Our Novel Biologics programs, including Insulin Tregopil, SiRNA, Itolizumab and Fusion Proteins, are on track. We continued to make progress in the pivotal Phase II/III clinical study with Insulin Tregopil, in people with Type 2 diabetes in India, with patients being dosed.


The Branded Formulations business, which includes sales in India and UAE, reported a revenue of Rs 149 Crore, a YoY growth of 14% in Q4FY18.

Branded Formulations – India business performance was led by some of the key brands like CANMAb™, BIOMAb EGFR®, TACROGRAF™ and PSORID™. Many of our key brands, holding a double digit market share, continue to be ranked amongst the ‘Top 3’ brands in their respective segment. KRABEVA®, our second oncology biosimilar launched in India in December 2017, crossed the ‘first 100 patients’ milestone in Q4FY18. However, the business continues to face operational challenges which has resulted in muted growth in FY 18.

The Branded Formulations business in UAE reported strong growth led by increase in sales of key branded generic products, newly introduced biosimilar Insulin Glargine, Glaricon and in-licensed novel products Jalra and Imprida.

NeoBiocon continues to be ranked among the Top 15 pharma companies in UAE, while improved market share of brands like Statix, Zargo and Valis have improved the Company’s ranking in the cardiovascular segment to No 4.


The Research Services business through Syngene registered a growth of 17% at Rs 387 Crore, on the back of a strong performance by the Chemical Development vertical and good traction in Discovery Services. Syngene has extended its agreement with Bristol-Myers Squibb (BMS) through 2026 and expanded the scope of its current collaboration.

During the quarter, Syngene signed a strategic, multi-year collaboration with GlaxoSmithKline (GSK) focusing on new drug discovery using Syngene’s discovery services platform. The collaboration also involves the setting up of a customized research facility for GSK. Syngene’s manufacturing facilities in Bengaluru were approved by the Japanese regulator, Pharmaceuticals and Medical Devices Authority (PMDA).

Fact Sheet – with Financials as per IND-AS

About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 120 countries, it is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from ‘Lab to Market’. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab), KRABEVA® (Bevacizumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. The Company has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin. Follow-us on Twitter: @bioconlimited

Earnings Call

The company will conduct a call at 9.00 AM IST on April 27, 2018 where the senior management will discuss the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is 1860 420 4242 or +91 44 7100 7405 (PIN – 740719#). Other toll numbers are listed in the conference call invite which is posted on the company website The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available from the conclusion of the call till May 3, 2018 (23:59 IST) on +91 22 3804 5003 Playback code: 943081#. Transcript of the conference call will be uploaded on the company website in due course.

DISCLAIMER: DISCLAIMER: This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

Author: Biocon Biologics
buy twitter followers